Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Overview of attention for article published in The Lancet, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 74 news outlets
blogs: 9 blogs
policy: 2 policy sources
twitter: 2332 X users
patent: 7 patents
facebook: 5 Facebook pages

wikipedia: 2 Wikipedia pages
reddit: 7 Redditors
guideline: 3 clinical guideline sources
bluesky: 2 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 366 Mendeley

So far, Altmetric has seen 5 public wall posts from 5 users.

Centre for Evidence-based Medicine, 16 Jan 2022

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01744-X/fulltext?dgcid=raven_jbs_etoc_email

Sociedad Latinoamericana de Alergia, Asma e Inmunología, 05 Sep 2021

Inhaled budesonide improves time to recovery, with a chance of also reducing hospital admissions or deaths (although our…

Sociedad Ecuatoriana De Alergia,asma E Inmunologia (SEAAI), 03 Sep 2021

Budesonida The trial began enrolment on April 2, 2020, with randomisation to budesonide from Nov 27, 2020, until March 31, 2021…

Morning Report Morsels, 20 Aug 2021

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01744-X/fulltext

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 1 additional Facebook posts.